Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
about
Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virusAntiviral therapy for recurrent liver graft infection with hepatitis C virusAntiviral treatment for hepatitis C virus infection after liver transplantation.A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti-hepatitis C target.Living-donor liver transplantation and hepatitis CLong-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.Management of the liver transplant patient.Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation.Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis.Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.Hepatitis C recurrence: the Achilles heel of liver transplantation.Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review.Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation.Sofosbuvir and Ribavirin for 24 Weeks Is An Effective Treatment Option for Recurrent Hepatitis C Infection After Living Donor Liver Transplantation.Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus.Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report.Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determiningTreatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers.Liver transplantation and hepatitis C
P2860
Q24201973-B571F85D-8E6B-4D32-9C8E-F99718A804DEQ24240405-394C7643-0964-427C-B2DE-7C9E4E8B62DCQ34340293-51F68B0C-C3B1-491B-903B-7E140A366D42Q35981554-2CC3F080-25B3-43CB-AD99-B60AA09CC737Q36587253-200ACA74-1EF1-45B8-9643-68E956286F96Q37118828-E817A6AF-FFE1-4190-BC92-2E271940579AQ37636100-1A322833-5D06-46E1-967A-9E13C9CD4944Q37973516-8A2054F8-7395-4969-9BA2-46B5C51ACAB4Q38028429-3DFF3EF9-9DDC-465C-9DA5-56AD8440A701Q38081919-B55B6DE5-17B8-49D0-8BE4-3D99FC27574FQ38174194-73FF8A35-6564-4820-8AD2-F87FA1832BA9Q38874771-17507008-F75E-4B76-8463-D8E32BE88625Q41673507-4941E53F-11A8-4C9E-BD2C-D2F04383AEE0Q41925906-2419E1B7-849F-423A-BF6A-2F5F21B1D472Q42245807-0ED16C0A-7881-4F85-ACCB-535EF451016DQ42978534-A75028C0-C202-4B13-B7FF-9DB6F2E8208AQ42998840-59FBB535-D940-4B5D-AC47-D9D4BBABFFB5Q43039969-6447BBFC-4145-48F2-B59A-7EB38E566E4EQ43456125-BCB33566-DA1A-45D4-95E3-599845513DC4Q45362112-4F4B626B-B875-47EA-B778-F2CEFFDB72F0Q50550145-4DD9019E-FF25-432A-96E9-34E267EC84B2Q58704499-15BBC140-76FC-4380-A6DD-A0ACD2ADAD46
P2860
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Clinical trial: peg-interferon ...... e after liver transplantation.
@en
Clinical trial: peg-interferon ...... e after liver transplantation.
@nl
type
label
Clinical trial: peg-interferon ...... e after liver transplantation.
@en
Clinical trial: peg-interferon ...... e after liver transplantation.
@nl
prefLabel
Clinical trial: peg-interferon ...... e after liver transplantation.
@en
Clinical trial: peg-interferon ...... e after liver transplantation.
@nl
P2093
P50
P1476
Clinical trial: peg-interferon ...... ce after liver transplantation
@en
P2093
A Colecchia
A D'Errico
A Gramenzi
Bologna Liver Transplantation Group (BLTG)
F B Bianchi
G Ballardini
P2860
P304
P356
10.1111/J.1365-2036.2008.03761.X
P407
P577
2008-06-11T00:00:00Z